Clinical Trials Directory

Trials / Unknown

UnknownNCT00073242

Low-Dose Leptin and the Formerly-Obese

Effects of Low-Dose Leptin on the Metabolic/Behavioral Phenotypes of the Formerly-Obese

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
25 (estimated)
Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · NIH
Sex
All
Age
19 Years – 45 Years
Healthy volunteers
Accepted

Summary

Our previous studies have demonstrated that there is substantial metabolic opposition to the maintenance of an altered body weight. Leptin is a protein secreted by fat cells and the circulating concentrations of leptin are directly proportional to fat mass. Leptin-deficiency is associated with severe obesity in rodents and in humans and the obesity is relieved by leptin administration. These studies examine the hypothesis that some of this metabolic opposition cto the maintenance of an altered body weight can be relieved by restoring circulating concentrations of the hormone leptin to the same range as at usual body weight in subjects who are maintaining a reduced body weight. The basic design of this study is to observe subjects at a 10% reduced body weight and then again at that reduced body weight while receiving physiological leptin or T3 supplementation.

Detailed description

We demonstrated a substantial metabolic resistance to maintenance of altered body weight. Leptin is secreted by fat cells in circulating concentrations that are directly proportional to fat mass. Leptin-deficiency is associated with severe obesity in rodents and in humans and the obesity is relieved by leptin administration. These studies examine the hypothesis that some of this metabolic opposition cto the maintenance of an altered body weight can be relieved by restoring circulating concentrations of the hormone leptin to the same range as at usual body weight in subjects who are maintaining a reduced body weight. The basic design of this study is to observe subjects at a 10% reduced body weight and then again at that reduced body weight while receiving physiological leptin or T3 supplementation.

Conditions

Interventions

TypeNameDescription
DRUGLeptinleptin administration
BEHAVIORALDietary modificationSubjects lose 10% of body weight via dietary restriction
DRUGT3 repletionadminister T3

Timeline

Start date
2000-07-01
Primary completion
2015-07-01
Completion
2015-07-01
First posted
2003-11-19
Last updated
2015-06-04

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00073242. Inclusion in this directory is not an endorsement.